INS and metabolic syndrome: Moreover, SalB reduces TG, FFA, and serum insulin levels, down-regulates hepatic gluconeogenic gene, and improves insulin intolerance, thus ameliorating dyslipidemia and hyperglycemia in db/db mice via the AMPK pathway [21].